2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-118084
    LS-104 368836-72-0 98%
    LS-104 (Tyrene CR-4) is a non-ATP-competitive kinase inhibitor against JAK2, Bcr-Abl and FLT3. LS-104 potently induces apoptosis in JAK2V617F-positive cells and inhibits JAK2 autophosphorylation and downstream signal transduction. LS-104 also inhibits proliferation and induces potent cytotoxic effects in FLT3 expressing leukemic cells. LS-104 is a hydroxystyryl-acrylonitrile compound, which is promising for research of myeloproliferative disorders and refractory/relapsed hematologic malignancies.
    LS-104
  • HY-118094
    8-iso Prostaglandin E1 21003-46-3 98%
    8-iso Prostaglandin E1 (Ovinonic acid; 8-iso-PGE1) is a spasmodic agent in canine pulmonary veins and can also cause vasodilation.
    8-iso Prostaglandin E1
  • HY-118148
    UK-66914 113049-11-9 98%
    UK-66914, is a class III antiarrhythmic agent that specifically acts on the delayed rectifier potassium current (I_K). UK-66914 is designed to prolong action potential duration (APD) and increase cardiac refractory period, thereby potentially terminating the reentry mechanism in arrhythmias without affecting the serious side effects of antiarrhythmic drugs associated with other ion channels such as Na+ and Ca2+ currents.
    UK-66914
  • HY-118172
    PD-307243 313533-41-4 98%
    PD-307243 is a hERG channel activator. PD-307243 can be used for research of arrhythmias.
    PD-307243
  • HY-118202
    (-)-Gallopamil 36622-40-9 98%
    (-)-Gallopamil exerts a selective modulation of the fast voltage-dependent inactivation. (-)-Gallopamil inhibits efficiently Cav1.2 constructs formed by β-subunits (promoting fast voltage-dependent inactivation). (-)-Gallopamil also accelerates the voltage-dependent phase of ICa decay (as well as the voltage-dependent decay of Ba2+ currents). (-)-Gallopamil is promising for research of antiarrhythmics.
    (-)-Gallopamil
  • HY-118220
    EP 171 122089-44-5 98%
    EP 171 is a TP receptor agonist and human platelet activator. EP 171 can induce constriction of guinea pig trachea, and the constriction can be inhibited by the TP receptor antagonist EP 092. EP 171 binds to TP receptors on intact human platelets with an IC50 of 2.9 nM.
    EP 171
  • HY-118294
    15-OH Tafluprost 130209-78-8 98%
    15-OH Tafluprost, a prostaglandin F2a (PGF2a) analog, relieves endothelin-1 (ET-1)-induced optic nerve head (ONH) blood flow impairment and ET-1-induced contraction of isolated ciliary artery segments.
    15-OH Tafluprost
  • HY-118335
    Prazobind 107021-36-3
    Prazobind (SZL 49), a prazosin analog, is a selective α1-adrenoceptor antagonist. Prazobind competes for alpha 1-adrenoceptor binding sites with a similar potency (IC50 of 1 nM) in tissues enriched in both the alpha 1A (hippocampus) and alpha 1B (liver) subtypes. Prazobind can be used for the study of blood pressure.
    Prazobind
  • HY-118339
    PF-4479745 1065110-43-1 98%
    PF-4479745 is a potent and selective 5-HT2C receptor agonist (EC50: 10 nM, ki: 15 nM). PF-4479745 can be used in the research of cardiovascular disease like hypertension.
    PF-4479745
  • HY-118410
    L-738167 163212-43-9 98%
    L-738167 is an orally active fibrogen receptor antagonist that prevents the binding of fibrinogen to GP IIb/IIIa. L-738167 can be utilized in thrombus research.
    L-738167
  • HY-118488
    L 640035 77167-93-2 98%
    L 640035 is athromboxaneantagonist.
    L 640035
  • HY-118674
    AK-2-38 122508-12-7 98%
    AK-2-38, a Nifedipine (HY-B0284) analogue, is a calcium channel antagonist. AK-2-38 also has partial agonist effects on isolated guinea pig left atrium.
    AK-2-38
  • HY-118689
    RA-2 1867107-62-7 98%
    RA-2 is a negative-gating modulator of KCa2/3 channels with an IC50 of 17 nM. RA-2 inhibits bradykinin-induced endothelium-derived hyperpolarization (EDH)-type relaxation in U46619-precontracted rings. RA-2 can help to define the physiologic and pathomechanistic roles of KCa2/3 in the vasculature, central nervous system, and during inflammation.
    RA-2
  • HY-118778
    KR-32568 852146-73-7 99.80%
    KR-32568 is a sodium/hydrogen exchanger-1 (NHE-1) inhibitor with an IC50 of 230 nM. KR-32568 has cardioprotective effects.
    KR-32568
  • HY-118779
    Rhazimine 93772-08-8 98%
    Rhazimine is an indole alkaloid that is a dual inhibitor of arachidonic acid metabolism and platelet activating factor-induced platelet aggregation.
    Rhazimine
  • HY-118833
    RAC 109 25360-99-0 98%
    RAC 109 is a local anesthetic. RAC 109 reduces ventricular conduction velocity and myocardial contractility in rabbits in a stereospecific manner (EC50=30 μM).
    RAC 109
  • HY-118938
    Hoquizil hydrochloride 23256-28-2 98%
    Hoquizil hydrochloride is a novel bronchodilator with oral activity, demonstrating phosphodiesterase inhibitory effects and potential for modulation of smooth muscle contraction.
    Hoquizil hydrochloride
  • HY-119013
    VPC32183 717110-61-7 98%
    VPC32183 is a competitive antagonist of LPA1 and LPA3 receptors. The activity of VPC32183 can inhibit lipid phosphatase 1 (LPP1), thereby preventing the activation of ERK(1/2) by dioctanoic acid diglyceride (DGPP 8:0). By reducing the expression of LPP1, VPC32183 can further reduce DGPP 8:0-induced ERK(1/2) activation. The effects of VPC32183 suggest that it may have a positive regulatory function in cell signaling processes.
    VPC32183
  • HY-119025
    L 681176 91386-17-3 98%
    L 681176 is an angiotensin-converting enzyme inhibitor that can be isolated from STREPTOMYCES sp. MA 5143a.
    L 681176
  • HY-119038
    ML-7 109376-83-2 98%
    ML-7 is a myosin light chain kinase inhibitor with the activity to inhibit superoxide anion (O(2)(-)) release in human neutrophils. ML-7 can affect the activity of neutrophils independently of myosin light chain kinase. ML-7 inhibits the extracellular O(2)(-) release of stimulated cells, but has no effect on the intracellular O(2)(-) production. ML-7 also strongly inhibits the binding of the intracellular compartment of oxide production to the cell membrane, indicating that it plays a key role in stimulated neutrophils. At the same time, ML-7 protects cardiac function from ischemia/reperfusion injury.
    ML-7
Cat. No. Product Name / Synonyms Application Reactivity